Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: A Southwest Oncology Group study (SWOG 9235

Urology

Volumn 58, Issue 1, 2001, Pages 53-58

  Kucuk, Omer ^a,i   Fisher, Emily ^b   Moinpour, Carol M ^b   Coleman, Dorothy ^c   Hussain, Maha H A ^a   Sartor, A Oliver ^d   Chatta, Gurkamal S ^e   Lowe, Bruce A ^f   Eisenberger, Mario A ^g   Crawford, E David ^h  

^a WAYNE STATE UNIVERSITY   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^d Medical Center   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; DIETHYLSTILBESTROL; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HORMONAL THERAPY; HORMONE RESISTANCE; HOT FLUSH; HUMAN; MALE; NAUSEA; ORCHIECTOMY; PAIN; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SURVIVAL TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DIETHYLSTILBESTROL; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0034943531     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01010-X     Document Type: Article

References (21)

1. Combined androgen blockade for the treatment of metastatic prostate cancer
2. Hormone-refractory ('D3') prostate cancer; refining the concept
3. Second-line hormonal therapy for advanced prostate cancer; a shifting paradigm
4. Bicalutamide ('Casodex') development; from theory to therapy
5. Bicalutamide (Casodex®) in the treatment of prostate cancer; history of clinical development
6. The short form McGill Pain Questionnaire
7. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer; a Canadian randomized trial with palliative end points
8. Development of symptom distress scale
9. Symptom distress, current concerns, and mood disturbance after diagnosis of life-threatening disease
10. The measurement of symptom distress
11. Measuring change over time; assessing the usefulness of evaluative instruments
12. Effect sizes for interpreting changes in health status
13. Treatment of metastatic prostatic cancer with low-dose prednisone; evaluation of pain and quality of life as pragmatic indices of response
14. Use of palliative endpoints to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer
15. Quality of life in prostate cancer patients
16. Bicalutamide for advanced prostate cancer; the natural versus treated history of disease
17. High dose bicalutamide for androgen independent prostate cancer; effect of prior hormonal therapy
18. Selection of androgen receptor mutations in prostate cancers treated with androgen antagonist
19. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer